Intel is set to unveil its first high-performance 3D-vision chips that it hopes will be able to perform the task of detecting cancerous cells at the nanoscale.

Intel will unveil the first of the new chips at the IFA tech show on Tuesday.

Intel chief executive Brian Krzanich said in an interview on CNBC that the chips will work on an Intel Xeon Phi processor, and will be a successor to the chips Intel already sells to the consumer market.

The chips will be Intel’s first chip to use Intel’s 3D sensing technology.

The chip has already been shown to be able detect cancerous tumor growth on a human tumor sample.

Intel has not yet announced pricing for the chips, but Krzanovich said the price is expected to be in the range of $500 to $700, and they will launch “very soon.”

Intel previously introduced a high-end version of its 3D scanners for the consumer and professional market, but it did not go into detail about the chips.

The technology is expected in devices from Apple and Samsung, but not Microsoft or Google.

Intel will make the chips available to developers in an open source version called OpenPVA.

The software will allow anyone to build 3D scans that can be tested on real-world specimens.

Intel’s 3DR (Physical Decoding Research) technology, which is also used by Microsoft’s Kinect, has been a key part of the company’s efforts to develop its imaging chips.

In addition to its current X-ray technology, the company also sells its 3DR sensors to universities for research purposes.

The technology is being used in Intel’s next generation chips.

Intel says that the new chip will use the technology in a new form factor and will have three times the resolution of existing 3DR chips.

Intel also plans to launch a new version of the Intel Optane memory that uses a “non-volatile memory” design.

It’s a form of memory that is used to store data in devices like laptops and tablets.

The new memory will be called Intel Optanium and will include Intel’s new 3D technology, according to Intel.